ProfileGDS5678 / 1432284_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 37% 36% 37% 38% 36% 47% 37% 36% 37% 37% 37% 41% 37% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0668944
GSM967853U87-EV human glioblastoma xenograft - Control 22.8544237
GSM967854U87-EV human glioblastoma xenograft - Control 32.8320236
GSM967855U87-EV human glioblastoma xenograft - Control 42.7914837
GSM967856U87-EV human glioblastoma xenograft - Control 52.8221638
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.906736
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1716947
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8279437
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7992436
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8384737
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8344637
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8036437
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9402941
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8470437